Crinetics Pharmaceuticals, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2024 | $350 M | No. 3 | $250 million to $1 billion | equity | SEC | |
| Feb 2018 | $60 M | No. 2 | $50 to $250 million | equity | SEC | |
| Oct 2015 | $18 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Crinetics Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2024).
SEC Form D · Mar 2024
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2024
That is all the official record says: Crinetics Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
In its own words
How the company describes itself to search engines on its website, word for word.
“Crinetics is here for endocrine disease patients who are eager to find therapies that provide effective disease control and more simplicity in their lives.”
Source: The company's website · as of Nov 15, 2026
Products and services#
No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.
Investors#
15 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 5AM Co-Investors IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| 5AM Partners IV, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| 5AM Ventures IV, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| OrbiMed Capital GP VI LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Perceptive Advisors LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2018) | SEC Form 3 |
| Perceptive Life Sciences Master Fund LTD | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2018) | SEC Form 3 |
| Versant Affiliates Fund V, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Versant Ophthalmic Affiliates I, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Versant Venture Capital V (Canada), LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Versant Venture Capital V, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Vivo Capital Fund VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Vivo Capital, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Vivo Capital Surplus Fund VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Vivo Capital VIII, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 36 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dana Vivaldi Pizzuti | Executive officer | Mar 2024 |
| James Vivaldi Hassard | Executive officer | Mar 2024 |
| Jeff Vivaldi Knight | Executive officer | Mar 2024 |
| Marc Scott Wilson | Executive officer | Mar 2024 |
| RICHARD SCOTT STRUTHERS, PhD | Executive officer | Mar 2024 |
| Stephen Vivaldi Betz | Executive officer | Mar 2024 |
| Richard Scott Struthers, Ph.D | Executive officer | Feb 2018 |
| Richard Scott Struthers | Executive officer | Nov 2015 |
| Stephen F. Betz | Executive officer | Nov 2015 |
| YunFei F. Zhu | Executive officer | Nov 2015 |
| Camille Scott Bedrosian, M.D. | Director | Mar 2024 |
| Caren Scott Deardorf | Director | Mar 2024 |
| Matthew Scott Fust | Director | Mar 2024 |
| RICHARD SCOTT STRUTHERS, PhD | Director | Mar 2024 |
| Rogerio Vivaldi Coelho, M.D. | Director | Mar 2024 |
| Stephanie Scott Okey | Director | Mar 2024 |
| WENDELL SCOTT WIERENGA, PhD | Director | Mar 2024 |
| WESTON SCOTT NICHOLS, PhD | Director | Mar 2024 |
| Jack B. Nielsen | Director | Feb 2018 |
| Mason Scott Freeman, M.D. | Director | Feb 2018 |
| Matthew K. Fust | Director | Feb 2018 |
| Richard Scott Struthers, Ph.D | Director | Feb 2018 |
| Steve Scott Kaldor, Ph.D | Director | Feb 2018 |
| Wendell Scott Wierenga, Ph.D | Director | Feb 2018 |
| Weston K. Nichols, Ph.D | Director | Feb 2018 |
| Mahendra Scott Shah | Director | Nov 2015 |
| Mason Scott Freeman | Director | Nov 2015 |
| Richard Scott Struthers | Director | Nov 2015 |
| Steve Scott Kaldor | Director | Nov 2015 |
| Wendell Scott Wierenga | Director | Nov 2015 |
About
Company in San Diego, United States.